Sofie Bekaert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sofie Bekaert has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Tim De Meyer
Department of Data Analysis and Mathematical Modelling, Faculty of Bioscience Engineering, Ghent University
3 shared publications - Dieter Deforce
Laboratory of Pharmaceutical Biotechnology, Ghent University, Ottergemsesteenweg 460, Gent, 9000, Belgium
2 shared publications - Dirk De Bacquer
Department of Public Health and Primary Care, Ghent University , Ghent
2 shared publications - Filip Pattyn
Center for Medical Genetics, Ghent University, Ghent, Belgium
2 shared publications - Filip Van Nieuwerburgh
Laboratory of Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
2 shared publications - Jan Hellemans
NXTGNT, Ghent University, Ghent, Belgium
2 shared publications
Latest Publications
- Open Access
- 18 May 2012
- Published by Springer Nature in BMC Medical Genomics
- Vol. 5 (1) , 17
Molecular diagnostics for congenital hearing loss including 15 deafness genes using a next generation sequencing platform
Background: Hereditary hearing loss (HL) can originate from mutations in one of many genes involved in the complex process of hearing. Identification of the genetic defects in patients is currently labor intensive and expensive. While screening with Sanger sequencing for GJB2 mutations is common, this is not the case for the other known deafness genes (> 60). Next generation sequencing technology (NGS) has the potential to be much more cost efficient. Published methods mainly use hybridization based target enrichment procedures that are time saving and efficient, but lead to loss in sensitivity. In this study we used a semi-automated PCR amplification and NGS in order to combine high sensitivity, speed and cost efficiency. Results: In this proof of concept study, we screened 15 autosomal recessive deafness genes in 5 patients with congenital genetic deafness. 646 specific primer pairs for all exons and most of the UTR of the 15 selected genes were designed using primerXL. Using patient specific identifiers, all amplicons were pooled and analyzed using the Roche 454 NGS technology. Three of these patients are members of families in which a region of interest has previously been characterized by linkage studies. In these, we were able to identify two new mutations in CDH23 and OTOF. For another patient, the etiology of deafness was unclear, and no causal mutation was found. In a fifth patient, included as a positive control, we could confirm a known mutation in TMC1. Conclusions: We have developed an assay that holds great promise as a tool for screening patients with familial autosomal recessive nonsyndromal hearing loss (ARNSHL). For the first time, an efficient, reliable and cost effective genetic test, based on PCR enrichment, for newborns with undiagnosed deafness is available.
- 18 May 2012
- Published by Springer Nature in BMC Medical Genomics
- Vol. 5 (1) , 17
Open AccessMolecular diagnostics for congenital hearing loss including 15 deafness genes using a next generation sequencing platform
Background: Hereditary hearing loss (HL) can originate from mutations in one of many genes involved in the complex process of hearing. Identification of the genetic defects in patients is currently labor intensive and expensive. While screening with Sanger sequencing for GJB2 mutations is common, this is not the case for the other known deafness genes (> 60). Next generation sequencing technology (NGS) has the potential to be much more cost efficient. Published methods mainly use hybridization based target enrichment procedures that are time saving and efficient, but lead to loss in sensitivity. In this study we used a semi-automated PCR amplification and NGS in order to combine high sensitivity, speed and cost efficiency. Results: In this proof of concept study, we screened 15 autosomal recessive deafness genes in 5 patients with congenital genetic deafness. 646 specific primer pairs for all exons and most of the UTR of the 15 selected genes were designed using primerXL. Using patient specific identifiers, all amplicons were pooled and analyzed using the Roche 454 NGS technology. Three of these patients are members of families in which a region of interest has previously been characterized by linkage studies. In these, we were able to identify two new mutations in CDH23 and OTOF. For another patient, the etiology of deafness was unclear, and no causal mutation was found. In a fifth patient, included as a positive control, we could confirm a known mutation in TMC1. Conclusions: We have developed an assay that holds great promise as a tool for screening patients with familial autosomal recessive nonsyndromal hearing loss (ARNSHL). For the first time, an efficient, reliable and cost effective genetic test, based on PCR enrichment, for newborns with undiagnosed deafness is available.
- Open Access
- 20 May 2010
- Published by Springer Nature in BMC Bioinformatics
- Vol. 11 (1) , 269
Analysing 454 amplicon resequencing experiments using the modular and database oriented Variant Identification Pipeline
Next-generation amplicon sequencing enables high-throughput genetic diagnostics, sequencing multiple genes in several patients together in one sequencing run. Currently, no open-source out-of-the-box software solution exists that reliably reports detected genetic variations and that can be used to improve future sequencing effectiveness by analyzing the PCR reactions.
- 20 May 2010
- Published by Springer Nature in BMC Bioinformatics
- Vol. 11 (1) , 269
Open AccessAnalysing 454 amplicon resequencing experiments using the modular and database oriented Variant Identification Pipeline
Next-generation amplicon sequencing enables high-throughput genetic diagnostics, sequencing multiple genes in several patients together in one sequencing run. Currently, no open-source out-of-the-box software solution exists that reliably reports detected genetic variations and that can be used to improve future sequencing effectiveness by analyzing the PCR reactions.
- 1 August 2008
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 28 (8) , 1563-1568
Femoral Plaques Confound the Association of Circulating Oxidized Low-Density Lipoprotein With Carotid Atherosclerosis in a General Population Aged 35 to 55 Years
Objective— Reported associations of oxidized low-density lipoprotein (oxLDL) with noninvasive measures of atherosclerosis are inconsistent. In the Asklepios Study cohort of asymptomatic subjects aged 35 to 55 years, we evaluated the relationship of circulating oxLDL with subclinical atherosclerosis in the carotid and femoral arteries. Methods and Results— Participants (n=2524, 51.5% females) completed a study questionnaire and underwent a clinical examination, blood analysis of oxLDL (mAb-4E6) and other risk markers, and ultrasound examination of intima-media thickness (IMT) and plaques in the left and right carotid and femoral arteries. oxLDL concentrations were highest in subjects with femoral plaques (n=658). In the group of subjects with carotid plaques (n=476), elevated oxLDL concentrations are related to concomitant femoral plaques detected in 54% of these subjects. Multivariate regression analyses (including anthropometric, hemodynamic, biochemical, and lifestyle variables) showed that femoral plaques are independently related to oxLDL whereas femoral IMT, carotid IMT, or carotid plaques were not independently associated with oxLDL. Conclusion— Circulating oxLDL is independently associated with femoral plaque and not with carotid artery wall damage.
- 1 August 2008
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 28 (8) , 1563-1568
Femoral Plaques Confound the Association of Circulating Oxidized Low-Density Lipoprotein With Carotid Atherosclerosis in a General Population Aged 35 to 55 Years
Objective— Reported associations of oxidized low-density lipoprotein (oxLDL) with noninvasive measures of atherosclerosis are inconsistent. In the Asklepios Study cohort of asymptomatic subjects aged 35 to 55 years, we evaluated the relationship of circulating oxLDL with subclinical atherosclerosis in the carotid and femoral arteries. Methods and Results— Participants (n=2524, 51.5% females) completed a study questionnaire and underwent a clinical examination, blood analysis of oxLDL (mAb-4E6) and other risk markers, and ultrasound examination of intima-media thickness (IMT) and plaques in the left and right carotid and femoral arteries. oxLDL concentrations were highest in subjects with femoral plaques (n=658). In the group of subjects with carotid plaques (n=476), elevated oxLDL concentrations are related to concomitant femoral plaques detected in 54% of these subjects. Multivariate regression analyses (including anthropometric, hemodynamic, biochemical, and lifestyle variables) showed that femoral plaques are independently related to oxLDL whereas femoral IMT, carotid IMT, or carotid plaques were not independently associated with oxLDL. Conclusion— Circulating oxLDL is independently associated with femoral plaque and not with carotid artery wall damage.
- Open Access
- 18 June 2007
- Published by Wiley in Aging Cell
- Vol. 6 (5) , 639-647
Telomere length and cardiovascular risk factors in a middle‐aged population free of overt cardiovascular disease
Summary: Evidence assembled over the last decade shows that average telomere length (TL) acts as a biomarker for biological aging and cardiovascular disease (CVD) in particular. Although essential for a more profound understanding of the underlying mechanisms, little reference information is available on TL. We therefore sought to provide baseline TL information and assess the association of prevalent CVD risk factors with TL in subjects free of overt CVD within a small age range. We measured mean telomere restriction fragment length of peripheral blood leukocytes in a large, representative Asklepios study cohort of 2509 community‐dwelling, Caucasian female and male volunteers aged approximately 35–55 years and free of overt CVD. We found a manifest age‐dependent telomere attrition, at a significantly faster rate in men as compared to women. No significant associations were established with classical CVD risk factors such as cholesterol status and blood pressure, yet shorter TL was associated with increased levels of several inflammation and oxidative stress markers. Importantly, shorter telomere length was associated with an increasingly unhealthy lifestyle, particularly in men. All findings were age and gender adjusted where appropriate. With these cross‐sectional results we show that TL of peripheral blood leukocytes primarily reflects the burden of increased oxidative stress and inflammation, whether or not determined by an increasingly unhealthy lifestyle, while the association with classical CVD risk factors is limited. This further clarifies the added value of TL as a biomarker for biological aging and might improve our understanding of how TL is associated with CVD.
- 18 June 2007
- Published by Wiley in Aging Cell
- Vol. 6 (5) , 639-647
Open AccessTelomere length and cardiovascular risk factors in a middle‐aged population free of overt cardiovascular disease
Summary: Evidence assembled over the last decade shows that average telomere length (TL) acts as a biomarker for biological aging and cardiovascular disease (CVD) in particular. Although essential for a more profound understanding of the underlying mechanisms, little reference information is available on TL. We therefore sought to provide baseline TL information and assess the association of prevalent CVD risk factors with TL in subjects free of overt CVD within a small age range. We measured mean telomere restriction fragment length of peripheral blood leukocytes in a large, representative Asklepios study cohort of 2509 community‐dwelling, Caucasian female and male volunteers aged approximately 35–55 years and free of overt CVD. We found a manifest age‐dependent telomere attrition, at a significantly faster rate in men as compared to women. No significant associations were established with classical CVD risk factors such as cholesterol status and blood pressure, yet shorter TL was associated with increased levels of several inflammation and oxidative stress markers. Importantly, shorter telomere length was associated with an increasingly unhealthy lifestyle, particularly in men. All findings were age and gender adjusted where appropriate. With these cross‐sectional results we show that TL of peripheral blood leukocytes primarily reflects the burden of increased oxidative stress and inflammation, whether or not determined by an increasingly unhealthy lifestyle, while the association with classical CVD risk factors is limited. This further clarifies the added value of TL as a biomarker for biological aging and might improve our understanding of how TL is associated with CVD.
- 1 October 2005
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 126 (10) , 1115-1122
Telomere length versus hormonal and bone mineral status in healthy elderly men
- 1 October 2005
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 126 (10) , 1115-1122
Telomere length versus hormonal and bone mineral status in healthy elderly men
- 6 August 2005
- Vol. 25 (4) , 3011-21
Telomere attrition as ageing biomarker.
Telomeres, the tandem-repeated hexamers at the termini of mammalian chromosomes, form protective complexes in association with specific proteins that together with telomerase, a specialised telomere-synthesizing enzyme, regulate telomere length. Telomere shortening is associated with cellular senescence and is implicated in tumorigenesis and cancer. Hence, mean telomere length has emerged as a replicative clock within each population of cells and the tissues and organs they build up in vitro and, consequently, as a biomarker for biological ageing in vivo. Chronological ageing per se does not parallel biological ageing, yet accurate and reliable biomarkers are lacking to distinguish between them. The question remains as to whether telomere dynamics is a determinant or merely a predictor of human biological age over and above chronological ageing. Although several reports have suggested a link between telomere attrition and ageing phenotypes and disorders, both reference values and a complete set of determinants are missing. Within this review, current evidence and knowledge on telomere length and telomere erosion rates reported, are summarised.
- 6 August 2005
- Vol. 25 (4) , 3011-21
Telomere attrition as ageing biomarker.
Telomeres, the tandem-repeated hexamers at the termini of mammalian chromosomes, form protective complexes in association with specific proteins that together with telomerase, a specialised telomere-synthesizing enzyme, regulate telomere length. Telomere shortening is associated with cellular senescence and is implicated in tumorigenesis and cancer. Hence, mean telomere length has emerged as a replicative clock within each population of cells and the tissues and organs they build up in vitro and, consequently, as a biomarker for biological ageing in vivo. Chronological ageing per se does not parallel biological ageing, yet accurate and reliable biomarkers are lacking to distinguish between them. The question remains as to whether telomere dynamics is a determinant or merely a predictor of human biological age over and above chronological ageing. Although several reports have suggested a link between telomere attrition and ageing phenotypes and disorders, both reference values and a complete set of determinants are missing. Within this review, current evidence and knowledge on telomere length and telomere erosion rates reported, are summarised.